Open AccessLow-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases
Author(s) -
Nienke Z. Borren,
Jay Luther,
Francis Colizzo,
John G. Garber,
Hamed Khalili,
Ashwin N. Ananthakrishnan
Publication year - 2019
Publication title -
journal of crohn's and colitis
Language(s) - English
Resource type - Journals
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1093/ecco-jcc/jjz020
Subject(s) - medicine , methotrexate , inflammatory bowel disease , odds ratio , ulcerative colitis , gastroenterology , confidence interval , crohn's disease , disease
Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when used with anti-TNF agents in IBD.